ASSET PURCHASE AGREEMENT
Exhibit 10.2
EXECUTION COPY
This ASSET PURCHASE AGREEMENT, dated November 6, 2014 (the “Agreement”), is by and among Amarantus Bioscience Holdings, Inc., a Nevada corporation (“Amarantus”), Regenicin, Inc., a Nevada corporation (“Regenicin”), Xxxxx Corporate Law Group, LLP (fka Cane Xxxxx, LLP, hereinafter “CCLG”), and Xxxxxx & Xxxx, LLP (“Xxxxxx & Xxxx”). The parties identified above are sometimes hereinafter individually referred to as a “Party” and collectively as the “Parties”.
WHEREAS, Xxxxxx & Xxxx represents Regenicin in the Lonza Litigation on a contingent-fee basis;
In consideration of the mutual covenants, agreements and representations and warranties contained herein, the parties, intending to be legally bound hereby, agree as follows:
ARTICLE I — Terms of Transaction
(a) all Cutanogen intellectual property rights, including patents, trademarks, know-how, and trade secrets related to or used in connection with PermaDerm and any other engineered skin technology for the treatment of severe xxxxx in humans (the “PermaDerm Technology”), including the PermaDerm trademark (PermaDerm®, Serial Number 85081741), and any other trademarks owned by Regenicin and used in connection with skin replacement technology for the treatment of severe xxxxx in humans, in each case existing as of the Effective Date; and
(b) Regenicin’s rights under the Lonza Litigation, and all claims against Lonza that Regenicin may have related to the Lonza Litigation (collectively, the “Purchased Assets”).
Except for the Purchased Assets, Amarantus is not acquiring any assets of Regenicin, including, without limitation, any inventory of Regenicin.
(a) In exchange for the sale and conveyance of the Purchased Assets as recited in Section 1.1 hereof, and in reliance upon the covenants, agreements and representations and warranties contained herein, Amarantus shall pay to Regenicin aggregate cash consideration of US$3,500,000 (Three Million Five Hundred Thousand United States Dollars) (the “Purchase Price”). The Purchase Price will be paid as follows: on the Closing Date: US$300,000 (Three Hundred Thousand United States Dollars) to Regenicin and US$200,000 (Two Hundred Thousand Dollars) to CCLG; on or before December 31, 2014: US$150,000 (One Hundred Fifty Thousand United States Dollars) to Regenicin and US$100,000 (One Hundred Thousand Dollars) to CCLG; and on January 31, 2015: US$2,550,000 (Two Million Five Hundred Fifty Thousand United States Dollars) to Regenicin and US$200,000 (Two Hundred Thousand United States Dollars) to CCLG (the “Payment Date”).
(b) Within five (5) business days after the Closing Date, Amarantus also shall provide to Regenicin US$3,000,000 (Three Million United States Dollars) worth of Amarantus shares whose value shall be determined using the volume weighted share price for the twenty day period immediately preceding the Closing Date or $0.08, whichever is lower (the “Stock Consideration”). All such shares shall be issued to Regenicin directly. Following the issuance of the Stock Consideration, Amarantus agrees to fully support any reasonable request made by Regenicin for assistance and/ or documentation related to the deposit of the Stock Consideration into Regenicin’s chosen stock account, including but not limited to providing Regenicin with a 144 opinion from Amarantus’ counsel at or after six months from the date of issuance of the Stock Consideration, and providing Regencin with any other documentation required by its Stock Broker or clearing house for the removal of any restrictive legend and/or the deposit of the Stock Consideration. The parties agree that a failure to provide such assistance and documentation shall be considered a material breach of this Agreement, and shall entitle Regenicin to injunctive relief, in addition to any other remedies provided by law.
2 |
For purposes of this Agreement, “Liability” means any direct or indirect liability, indebtedness, obligation, expense, debt, claim, loss, tax, damage, deficiency, guaranty or endorsement of any nature, of or by any Person (as defined in Section 2.3 hereof), whether absolute or contingent, known or unknown, secured or unsecured, recourse or non-recourse, filed or unfiled, accrued or unaccrued, due or to become due, or liquidated or unliquidated.
ARTICLE II – Mutual Representations and Warranties
Each Party represents and warrants to the other Parties as follows:
3 |
ARTICLE III
Intentionally left out
ARTICLE IV Representations and Warranties of Regenicin
Regenicin represents and warrants to Amarantus as follows:
4.1 Title to and Adequacy of Purchased Assets.
(a) Schedule 1.1 sets forth a complete and accurate list of all Trademarks owned or used by Regenicin in connection with the PermaDerm Technology.
(b) Regenicin has good and valid title to and unqualified right to use and transfer to Amarantus, all of the Purchased Assets, free and clear of all liens, claims, prior assignments, mortgages, security interests, and other title retention arrangements, restrictions or encumbrances whatsoever (collectively, “Liens”), other than the perfected security interest held by CCLG, or any payment except maintenance fees. Regenicin has not granted any right in the Purchased Assets to any other Person and, to the best of the Regenicin’s knowledge, no other Person has any right in the Purchased Assets.
(c) To the knowledge of Regenicin, the use of the Purchased Assets does not infringe or is alleged to infringe or misappropriate any patent, trademark, service xxxx, trade name, domain name or other proprietary right of any Person. Regenicin has received no notice of, and to the best of the Regenicin’s knowledge there is no basis for, any claim or demand of any Person, or any proceeding that is pending or threatened, which challenge the exclusive rights of Regenicin in respect of any of the Purchased Assets. To Regenicin’s knowledge, except as claimed in the Lonza Litigation, no other Person infringes or misappropriates any Intellectual Property among the Purchased Assets.
4 |
(d) Regenicin is the owner of the Trademarks and does not know of any prior use of the Trademarks or any third party claim of any prior use of the Trademarks or any confusingly similar xxxx on or in connection with the PermaDerm Technology, and there are no challenges to Regenicin’s ownership of the Trademarks or Regenicin’s right to assign the Trademark and its associated goodwill to Amarantus. Regenicin has not abandoned use of the Trademarks and Regenicin has reasonably continuously used the Trademarks in commerce since its adoption, as set forth in the Trademark registration, in connection with the goods or services listed in the Trademark registrations.
(e) Notwithstanding anything contained herein, Regencin specifically disclaims any representation or warranty as to: (1) any asserted claim of ownership of the Purchased Assets that may be made by Lonza or any of its affiliates; and (2) as to the quality, value or commerciality of the Knowhow or IP which is the subject of the Lonza Litigation.
ARTICLE V — Representations and Warranties of CCLG
CCLG represents and warrants to Amarantus as follows:
5.1 No Foreclosure. CCLG has not foreclosed on Regenicin’s assets under the Promissory Note.
5 |
ARTICLE VI Representations and Warranties of Xxxxxx & Xxxx
Xxxxxx & Xxxx represents and warrants to Amarantus as follows:
ARTICLE VII – Additional Covenants
7.3 Following the Closing Date, Regenicin will not, at any time, use or represent that it is continuing to use the Purchased Assets. Regenicin will not use, register or attempt to register any domain name, trademark, trade name, logo, service xxxx or other designation of origin which includes the term “PermaDerm” (or any variation thereof that is likely to cause confusion) after the Closing Date. In the event that Regenicin registers or otherwise acquires any rights to any Trademarks or any domain names. If it is determined that any such trademark or domain name filed by Regenicin is confusingly similar to PermaDerm, upon request from Amarantus, Regenicin will promptly transfer ownership thereof to Amarantus; provided, however, that Amarantus will prior to such transfer reimburse Regenicin for the actual documented fees associated with acquiring and transferring ownership of the trademark or Domain name.
6 |
7.4 Regenicin shall not in any manner take any action which is designed, intended or might be reasonably anticipated to have the effect of adversely affecting the value or reputation of the Purchased Assets or the use by Amarantus of the Purchased Assets. Neither Regenicin nor any of its affiliates shall, directly or indirectly, make (or cause to be made) to any Person any disparaging, derogatory or other negative or false statement about Amarantus, the Purchased Assets, or the PermaDerm engineered skin technology; provided, however , that nothing in this paragraph shall preclude Regenicin or its affiliates from enforcing its rights under this Agreement or any Transaction Document, or complying truthfully with a legal obligation.
7.5 Neither Amarantus nor any of its affiliates shall, directly or indirectly, make (or cause to be made) to any Person any disparaging, derogatory or other negative or false statement about Regenicin or Regenicin’s technology; provided, however , that nothing in this paragraph shall preclude Amarantus or its affiliates from enforcing any of its rights under this Agreement or any Transaction Document, or complying truthfully with a legal obligation.
7.6 Regenicin shall take whatever actions may be necessary to cause any of its affiliates to adhere to the terms of this Article VII.
7.7 In the event of any breach or threatened breach by Regenicin, or its affiliates, of any provision of this Article VII, Amarantus shall be entitled to injunctive or other equitable relief, restraining such party from engaging in conduct that would constitute a breach of the obligations of Regenicin or its affiliates under this Article VII. Such relief shall be in addition to and not in lieu of any other remedies that may be available, including an action for the recovery of monetary damages.
7.8 In the event of any breach or threatened breach by Amarantus, or its affiliates, of any provision of this Article VII, Regenicin shall be entitled to injunctive or other equitable relief, restraining such party from engaging in conduct that would constitute a breach of the obligations of Amarantus, or its affiliates under this Article VII. Such relief shall be in addition to and not in lieu of any other remedies that may be available, including an action for the recovery of monetary damages
7.9 Amarantus shall take whatever actions may be necessary to cause all of its affiliates to adhere to the terms of this Article VII.
7 |
(a) In any settlement of the Lonza Litigation after the Closing Date, Amarantus will obtain from Lonza and its affiliates, a complete release of Regenicin related to the subject matter of the Lonza Litigation and a complete release as to any future claims made by Lonza against Regenicin as and for any action done prior to such settlement that relate to the subject matter of the Lonza Litigation.
(b) After the Closing Date, Regenicin agrees not to bring any claims against Lonza or its affiliates related to the Lonza Litigation unless payment is not made as provided in Section 1.2.
(c) Amarantus agrees not to dismiss the Lonza Litigation until the entire Purchase Price has been paid under this Agreement.
ARTICLE VIII — Indemnification
8.1 Regenicin shall indemnify Amarantus and its affiliates and each of their respective stockholders, officers, directors, managers, members, employees, agents, partners, representatives, successors and assigns (collectively, the “Amarantus Indemnified Parties”) and save and hold each of them harmless from and against and pay on behalf of or reimburse such Amarantus Indemnified Parties as and when incurred for any Amarantus Damages, which any such Amarantus Indemnified Party may suffer, sustain or become subject to, as a result of, in connection with, relating or incidental to or by virtue of: (a) any breach by Regenicin of any representation or warranty made by Regenicin in this Agreement, (b) any non-fulfillment or breach of any covenant, agreement or other provision by Regenicin under this Agreement or any other Transaction Document, or (c) any Excluded Liability. As used herein, “Amarantus Damages” means any and all claims, Liabilities, losses, damages, costs and expenses, including court costs and reasonable attorneys’ fees and expenses (including any such fees and expenses incurred by a Amarantus Indemnified Party to assume the defense of any third party litigation or other claim against it that is subject to the foregoing indemnification).
8 |
8.2 Amarantus shall indemnify Regenicin and its affiliates and each of their respective stockholders, officers, directors, managers, members, employees, agents, partners, representatives, successors and assigns (collectively, the “Regenicin Indemnified Parties”) and save and hold each of them harmless from and against and pay on behalf of or reimburse such Regenicin Indemnified Parties as and when incurred for any Regenicin Damages, which any such Regenicin Indemnified Party may suffer, sustain or become subject to, as a result of, in connection with, relating or incidental to or by virtue of: (a) any breach by Amarantus of any representation or warranty made by Amarantus in this Agreement, (b) any non-fulfillment or breach of any covenant, agreement or other provision by Amarantus under this Agreement or any other Transaction Document, (c) the use of the Purchased Assets after the Closing Date except to the extent relating to an Excluded Liability or the negligence or willful misconduct of a Regenicin Indemnified Party, and (d) from the Closing Date, any claim or counterclaims brought by Lonza against Regenicin under the Lonza Litigation or that could have been brought as a counterclaim under the Lonza Litigation. As used herein, “Regenicin Damages” means any and all claims, Liabilities, losses, damages, costs and expenses, including court costs and reasonable attorneys’ fees and expenses (including any such fees and expenses incurred by a Regenicin Indemnified Party to assume the defense of any third party litigation or other claim against it that is subject to the foregoing indemnification).
8.3 Any indemnification provided for herein shall be effected by wire transfer of immediately available funds to an account(s) designated by the applicable Indemnified Party , within ten (10) days after the final determination of the indemnification amount.
ARTICLE IX — Additional Agreements
9.1 Further Assurances.
(a) At reasonable times and upon reasonable notice, upon request of Amarantus or Regenicin, as the case may be, and without further consideration, Regenicin or Amarantus shall deliver to the other all further deeds, bills of sale, endorsements, assignments, financing or other statements, agreements and other instruments of conveyance, transfer, assignment and delivery and all powers of attorney, and otherwise provide assistance, as may be required or reasonably requested for the better conveyance, transfer, assignment or delivery of the Purchased Assets, including to enforce and protect the right, title and interest in and enjoyment of all of the Intellectual Property and associated rights assigned, transferred and conveyed to Amarantus pursuant to this Agreement, or otherwise to effectuate all of the transactions contemplated by this Agreement.
(b) Purchase Price Allocation. After the Closing, the parties shall make consistent use of the allocation of the Purchase Price among the Purchased Assets based on the reasonable judgment of Amarantus (the “Allocation”), for all tax purposes and in all filings, declarations and reports with the Internal Revenue Service (“IRS”) in respect thereof, including the reports required to be filed under Section 1060 of the United States Internal Revenue Code. Amarantus shall prepare and deliver IRS Form 8594 to Regenicin within seventy-five (75) days after the Payment Date to be filed with the IRS. In any proceeding related to the determination of any tax, neither Amarantus nor Regenicin shall contend or represent that the Allocation is not a correct allocation. Nothing contained herein shall be construed to allow Amarantus to provide or file any form (1099 or otherwise) with the IRS for CCLG with regard to the payment of the balance due on Regenicin’s Note owed to CCLG.
9 |
9.2 Public Announcements. No Party will release or permit to be released any press release, public announcement or other publicity regarding this Agreement or the transactions contemplated hereby, except with the prior written consent of the other Parties or as otherwise required by law.
9.3 Expenses. Except as otherwise expressly provided herein, each party hereto shall pay its own expenses, including, without limitation, the fees and expenses of its counsel, incurred in connection with this Agreement and the transactions contemplated hereby.
ARTICLE X — Closing
10.1 Closing. The closing (the “Closing”) for the consummation of the transactions contemplated by this Agreement shall be deemed effective as of 12:01 a.m. ET on November [6], 2014 (the “Closing Date”).
10.2 Deliveries at Closing. At Closing, in addition to the other actions contemplated elsewhere herein,
(a) Each Party shall execute and deliver to the other Parties electronically, an executed copy of the signature page of this Agreement
(b) Regenicin shall deliver to Amarantus such files, documents and personal property in whatever form or media relating to the Purchased Assets as may be required hereunder (including as necessary any xxxx of sale.)
(c) Amarantus shall deliver to Regenicin:
(i) the portion of the Purchase Price due Regenicin as of the Closing Date; and
(d) Amarantus shall deliver to CCLG:
(i) the portion of the Purchase Price due CCLG as of the Closing Date.
(e) Amarantus shall deliver to Xxxxxx & Xxxx:
(i) the Litigation Costs set forth in Section 1.3.
10 |
ARTICLE XI — Miscellaneous
11.1 Governing Law; Dispute Resolution.
(a) The Parties hereto hereby irrevocably submit to the non-exclusive jurisdiction of any federal or state court located within the State of Nevada over any dispute arising out of or relating to this Agreement or any of the transactions contemplated hereby and each Party hereby irrevocably agrees that all claims in respect of such dispute or any suit, action proceeding related thereto may be heard and determined in such courts. The Parties hereby irrevocably waive, to the fullest extent permitted by applicable law, any objection which they may now or hereafter have to the laying of venue of any such dispute brought in such court or any defense of inconvenient forum for the maintenance of such dispute. Each of the Parties hereto agrees that a judgment in any such dispute may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.
(b) Each of the Parties hereto hereby consents to process being served by any Party to this Agreement in any suit, action or proceeding by the mailing of a copy thereof in accordance with the provisions of Section 11.4.
11.2 Entire Agreement. This Agreement, including the Schedule and Exhibits hereto, contains the entire Agreement between the parties hereto with respect to the subject matter hereof. All representations, promises and prior or contemporaneous understandings between the parties with respect to the subject matter hereof are merged into and expressed in this instrument, and any and all prior agreements between the parties with respect to the subject matter hereof are hereby terminated and cancelled.
11.3 Survival. All representations and warranties by the parties hereto contained in this Agreement shall survive the Closing under this Agreement.
(a) | Amarantus: |
Amarantus Biosciences Holdings, Inc.
c/x Xxxxxxx Labs @ QB3
000 Xxxxxxx Xx.
Xxx Xxxxxxxxx, XX 00000
Phone: 000 000 0000
Fax: 000 000 0000
Attention: Xxxxxx Xxxxxxxxxxx, President & CEO
11 |
Copy to:
Xxxxxxx Xxxxxxx, Esq.
Sichenzia Xxxx Xxxxxxxx Xxxxxxx LLP
0000 Xxxxxx xx xxx Xxxxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Phone: (000) 000-0000
Facsimile: (000) 000-0000
(b) | RGIN: |
Regenicin, Inc.
00 Xxxx Xxxxx
Xxxxxx Xxxxx, XX 00000
Phone: 000-000-0000
Facsimile:
Attn: Xxxxx XxXxx
(c) | CCLG: |
Xxxxx Corporate Law Group, LLP
0000 X Xxxx Xxxxxxx Xx
Xxx Xxxxx, XX 00000
Phone: 000-000-0000
Facsimile: 000-000-0000
Attn: Xxxxx Xxxxx
(d) | Xxxxxx & Xxxx: |
Xxxxxx & Xxxx, LLP
The Pinnacle Building
0000 Xxxxxxxxx Xxxx, Xxxxx 0000
Xxxxxxx, XX 00000
Phone: 000-000-0000
Facsimile: 000-000-0000
Attn: Xxxx X. Xxxxxxxxx
12 |
[signature page follows]
13 |
AMARANTUS BIOSCIENCE HOLDINGS, INC. | ||
By: | /s/ Xxxxxx Xxxxxxxxxxx | |
Name: Xxxxxx Xxxxxxxxxxx | ||
Title: President & CEO | ||
REGENICIN, INC. | ||
By: | /s/ Xxxxxxx X. XxXxx | |
Name: Xxxxxxx X. XxXxx | ||
Title: CEO/Chairman | ||
XXXXX CORPORATE LAW GROUP | ||
By: | /s/ Xxxxxx Xxxx | |
Name: Xxxxxx Xxxx | ||
Title: Manager/Member | ||
XXXXXX & XXXX, LLP | ||
By: | /s/ Xxxx X. Xxxxxxxxx | |
Name: Xxxx X. Xxxxxxxxx | ||
Title: Partner |
[signature page to Asset Purchase Agreement]
14 |